Kestra Private Wealth Services LLC Has $477,000 Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Kestra Private Wealth Services LLC decreased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 14.2% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 3,920 shares of the medical equipment provider’s stock after selling 648 shares during the period. Kestra Private Wealth Services LLC’s holdings in Zimmer Biomet were worth $477,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of ZBH. Schechter Investment Advisors LLC boosted its holdings in Zimmer Biomet by 21.6% during the third quarter. Schechter Investment Advisors LLC now owns 4,241 shares of the medical equipment provider’s stock worth $476,000 after purchasing an additional 752 shares during the last quarter. Atria Wealth Solutions Inc. increased its position in shares of Zimmer Biomet by 5.9% in the third quarter. Atria Wealth Solutions Inc. now owns 20,566 shares of the medical equipment provider’s stock valued at $2,312,000 after acquiring an additional 1,144 shares during the last quarter. International Assets Investment Management LLC boosted its position in Zimmer Biomet by 11,244.9% during the fourth quarter. International Assets Investment Management LLC now owns 66,935 shares of the medical equipment provider’s stock valued at $8,146,000 after purchasing an additional 66,345 shares during the last quarter. Amalgamated Bank grew its stake in Zimmer Biomet by 3.0% in the third quarter. Amalgamated Bank now owns 56,166 shares of the medical equipment provider’s stock valued at $6,303,000 after purchasing an additional 1,631 shares in the last quarter. Finally, Sequoia Financial Advisors LLC increased its position in shares of Zimmer Biomet by 37.5% during the 4th quarter. Sequoia Financial Advisors LLC now owns 155,965 shares of the medical equipment provider’s stock worth $18,981,000 after purchasing an additional 42,539 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Insider Buying and Selling

In other Zimmer Biomet news, VP Chad F. Phipps sold 26,156 shares of the firm’s stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total value of $3,364,184.72. Following the transaction, the vice president now directly owns 44,145 shares of the company’s stock, valued at approximately $5,677,929.90. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.70% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Citigroup raised their target price on shares of Zimmer Biomet from $134.00 to $140.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $140.00 target price on shares of Zimmer Biomet in a report on Friday, February 9th. Canaccord Genuity Group reiterated a “hold” rating and set a $130.00 price target on shares of Zimmer Biomet in a report on Friday, February 23rd. Barclays raised their price objective on Zimmer Biomet from $120.00 to $130.00 and gave the company an “underweight” rating in a research report on Monday, February 12th. Finally, Truist Financial dropped their price target on Zimmer Biomet from $137.00 to $130.00 and set a “hold” rating on the stock in a research note on Friday. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $135.40.

Zimmer Biomet Price Performance

Shares of Zimmer Biomet stock opened at $120.57 on Tuesday. The company has a 50-day simple moving average of $125.17 and a two-hundred day simple moving average of $120.32. Zimmer Biomet Holdings, Inc. has a twelve month low of $102.00 and a twelve month high of $147.50. The stock has a market capitalization of $24.80 billion, a price-to-earnings ratio of 26.10, a price-to-earnings-growth ratio of 2.23 and a beta of 1.03. The company has a quick ratio of 0.80, a current ratio of 1.66 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.87 by $0.07. Zimmer Biomet had a return on equity of 12.70% and a net margin of 12.93%. The business had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. During the same period in the previous year, the company posted $1.89 earnings per share. The firm’s revenue for the quarter was up 3.2% compared to the same quarter last year. Analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.1 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, April 30th. Investors of record on Friday, March 29th were paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.80%. The ex-dividend date was Wednesday, March 27th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 20.78%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.